Biogen announced that its current candidate for an Alzheimer’s drug was ineffective, resulting in an 18 billion dollar loss in valuation – that number should provide a sense of both the need and market for an effective treatment.
Biogen
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!
Popular articles
ACSH Podcasts
